Aspen Aerogels (ASPN) to Release Earnings on Wednesday

Aspen Aerogels (NYSE:ASPN - Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Aspen Aerogels to post earnings of ($0.01) per share for the quarter. Aspen Aerogels has set its FY24 guidance at more than $0.09 EPS.Persons that are interested in registering for the company's earnings conference call can do so using this link.

Aspen Aerogels (NYSE:ASPN - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The construction company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.05 by $0.16. The firm had revenue of $117.80 million for the quarter, compared to analyst estimates of $101.99 million. Aspen Aerogels had a net margin of 0.39% and a return on equity of 0.74%. The business's revenue for the quarter was up 144.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.22) EPS. On average, analysts expect Aspen Aerogels to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Aspen Aerogels Trading Up 0.4 %

Aspen Aerogels stock traded up $0.07 during mid-day trading on Wednesday, hitting $18.30. The company's stock had a trading volume of 1,210,069 shares, compared to its average volume of 1,497,477. Aspen Aerogels has a 1 year low of $7.37 and a 1 year high of $33.15. The company has a current ratio of 3.46, a quick ratio of 2.82 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $1.39 billion, a PE ratio of -41.43 and a beta of 2.16. The stock's fifty day moving average is $25.01 and its two-hundred day moving average is $24.61.

Insider Buying and Selling at Aspen Aerogels

In other news, CFO Ricardo C. Rodriguez sold 32,465 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $30.14, for a total value of $978,495.10. Following the completion of the transaction, the chief financial officer now owns 20,790 shares in the company, valued at $626,610.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Aspen Aerogels news, CEO Donald R. Young sold 63,355 shares of the stock in a transaction on Monday, September 30th. The stock was sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the transaction, the chief executive officer now owns 483,640 shares of the company's stock, valued at $14,523,709.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Ricardo C. Rodriguez sold 32,465 shares of the company's stock in a transaction on Monday, August 26th. The stock was sold at an average price of $30.14, for a total value of $978,495.10. Following the sale, the chief financial officer now owns 20,790 shares of the company's stock, valued at approximately $626,610.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Barclays initiated coverage on Aspen Aerogels in a research note on Tuesday, August 6th. They set an "overweight" rating and a $27.00 target price on the stock. Roth Mkm restated a "buy" rating and issued a $36.00 price objective on shares of Aspen Aerogels in a report on Wednesday, August 21st. Piper Sandler reduced their target price on shares of Aspen Aerogels from $36.00 to $33.00 and set an "overweight" rating on the stock in a report on Tuesday, October 22nd. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Aspen Aerogels in a research note on Wednesday, October 16th. Finally, Benchmark restated a "buy" rating and issued a $14.00 price objective on shares of Aspen Aerogels in a report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Aspen Aerogels currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.40.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.